Mecamylamine for Autonomic Dysreflexia Prophylaxis

Status unconfirmed · Phase 4

Conditions studied: Spinal Cord Injuries

In brief

This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

Key facts

Study ID

NCT03914677

Run by

Wayne State University

People needed

5

Starts

2019-06-13

Expected to finish

2020-12-31

Last updated by the study team

2019-10-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• chronic (>1 year) SCI at T6 or above, American Spinal Injury Association grade A, B, or C
• negative serum pregnancy test for females

You may not qualify if…

• history of arrhythmia, cardiovascular disease, cerebral aneurysm
• contraindications to use of mecamylamine or midodrine (pregnancy, nursing, glaucoma, kidney disease, pyloric stenosis, arteriosclerosis, or concurrent use of a sulfonamide antibiotic)
• dependence on reflex voiding for bladder management (mecamylamine may cause urinary retention)

Where it is running

• Wayne State University — Detroit, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.